ALSO NOTED: Takeda offering bonuses at Millennium; Atypicals were first-, second-, and third-line in FL;

> Takeda Pharmaceuticals is planning to offer retention bonuses to Millennium Pharma workers, hoping to keep employees through Takeda's takeover of the Boston company. Report

> A handpicked panel of experts tied to makers of atypical antipsychotics installed the meds as first, second, and possibly even third-line treatments for schizophrenia in Florida. Report

> Jazz Pharmaceuticals' Luvox drug won FDA approval for treatment of social anxiety disorder and obsessive-compulsive disorders; the med already was approved as an antidepressant. Release

> Novartis and Cipla both plan to launch oral treatments in India for thalassaemia, a genetic blood disorder previously treated only with injectables. Report

> Alpharma's board authorized a $150 million share repurchase plan. Report

> Perrigo got final FDA approval for its over-the-counter generic form of Zyrtec oral solution. Release

> After struggling for months to sell the company or some of its assets, PDL BioPharma has announced plans to spin off its biotech operations into a publicly-traded company. Report

> At a hearing on stem cells, the FDA set a high bar for the treatments, saying that any therapies would have to have very compelling data in order to move into human trials. Report

And Finally... Have you clicked a link in this newsletter? You may not have been able to help yourself, a new study shows. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.